Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 USD | +1.75% | -6.07% | -88.68% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Apr. 02 | JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform | MT |
Business Summary
Number of employees: 41
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 17-01-31 | |
Eric Easom
FOU | Founder | 56 | 17-01-31 |
Lucy Day
DFI | Director of Finance/CFO | 65 | 19-10-31 |
Paul Eckburg
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-10-31 |
Jennifer Huber
LAW | General Counsel | - | - |
Josh Eizen
LAW | General Counsel | - | - |
Corporate Officer/Principal | - | 19-10-31 | |
Kevin Krause
PRN | Corporate Officer/Principal | 49 | 21-07-31 |
Annie Yoshiyama
AUD | Comptroller/Controller/Auditor | 41 | 23-09-14 |
Sanjay Chanda
PRN | Corporate Officer/Principal | 59 | 19-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 60 | 17-01-31 | |
Patricia Martin
BRD | Director/Board Member | 63 | 21-03-31 |
Melvin Spigelman
BRD | Director/Board Member | 75 | 22-01-31 |
Director/Board Member | 58 | 22-05-08 | |
Robin Readnour
BRD | Director/Board Member | 59 | 19-10-31 |
Stephanie Wong
BRD | Director/Board Member | 50 | 21-03-31 |
Kabeer Aziz
BRD | Director/Board Member | 34 | 19-10-31 |
Eric Easom
FOU | Founder | 56 | 17-01-31 |
Gilbert Marks
BRD | Director/Board Member | 66 | 20-01-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 29,770,375 | 22,048,825 ( 74.06 %) | 0 | 74.06 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.68% | 69.07M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ANTX Stock
- Company AN2 Therapeutics, Inc.